Dorocubicel is under clinical development by ExCellThera and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dorocubicel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dorocubicel overview
Dorocubicel (ECT-001) cell therapy is under development for the treatment of blood cancers, multiple myeloma, anemia, relapsed and refractory acute myeloid leukemia, relapsed and refractory acute lymphoid leukemia, relapsed myelodysplastic syndrome, chronic myelogenous leukemia, lymphoma. It is administered through intravenous route. The ECT-001 technology is a combination of a small molecule, UM171, and an optimized culture system expanding cord blood.
It was also under development for the treatment of graft versus host disease (GVHD, blood cancer, thalassemia, sickle cell disease, Crohn's disease, colitis, autoimmune diseases, inflammatory diseases and metabolic diseases.
ExCellThera overview
ExCellThera is a biotechnology company that develops molecules and bioengineering solutions to treat hematologic disorders and malignancies by expanding stem and immune cells. It is investigating hematopoietic stem cell (HSC) based cell and gene therapies in the fields of oncology, hematology, and immunology. The company utilizes its ECT-001 cell therapy technology that integrates a proprietary small molecule and UM171 cell therapy used to treat blood cancers, including leukemias and myelodysplasias. It operates its offices in Canada. ExCellThera is headquartered in Montreal, Quebec, Canada.
For a complete picture of Dorocubicel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
